COMMUNIQUÉS West-GlobeNewswire

-
Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference
25/03/2019 -
Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer
25/03/2019 -
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences
25/03/2019 -
Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference
25/03/2019 -
VBL Therapeutics to Present at Upcoming Conferences in April
25/03/2019 -
BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
25/03/2019 -
Strongbridge Biopharma plc Announces Presentation of New Data Analyses from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
25/03/2019 -
OpGen and Merck’s ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship
25/03/2019 -
Radient Technologies Inc. Announces Addition of Three Key Members to its Management Team
25/03/2019 -
Neutral Connect Networks Acquires Connectivity Wireless Solutions Extending its Leadership in the Growing Neutral-Host Infrastructure and Services Business
25/03/2019 -
Translate Bio to Participate in Upcoming Investor Conferences
25/03/2019 -
Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes
25/03/2019 -
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program
25/03/2019 -
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
25/03/2019 -
Notice of Results
25/03/2019 -
Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
25/03/2019 -
MediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results
25/03/2019 -
Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC™ Protein Degrader, ARV-110
25/03/2019 -
Canopy Rivers Portfolio Company Licensed by Health Canada, Triggering Long-Term Cash Flow Stream
25/03/2019
Pages